Skip to content
Company Analysis

Atara Biotherapeutics, Inc. ATRA

A comprehensive view of key metrics, scores, and financial health for Atara Biotherapeutics, Inc.

Overview of Atara Biotherapeutics, Inc.

ATRA NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Atara Biotherapeutics, Inc. (ATRA), is a Micro Cap company, in the Biotechnology industry, last closed at $8.66, about 230.7% undervalued vs fair value, -38.4% 1Y return, ranked 917/1145 in sector.
Metrics P/E 7.0× Rev Growth -6.3% ROE -48.2% Gross Margin 82.4%
USD 8.66
4.34%
(Delayed)
• Vol 90d: 66.7%
52-Week Range
Market Cap
$86.93M
Enterprise Value
$83.71M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 89%
Updated: Oct 24
Top Beats
No strong beats yet

Quick Facts

Website https://www.atarabio.com
HQ Thousand Oaks, CA
Employees 38
Fiscal year Dec 31

Next Events

Earnings Nov 12 Estimated

Fair Value Snapshot

Bear Base Bull
$26
$29
$31
Current: $8.66 +231% vs base

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$8.5M
-66.1%%
Total Revenue
$120.8M
-6.3%%
Net Income
$32.7M
138.3%%
Operating Expense
$63.7M
-66.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
2.0 months
Poor

Critical: Cash runway under 12 months

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Atara Biotherapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
56
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Cost Leadership Position Operating margin at 93.6th percentile with strong OpEx control demonstrates cost leadership.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.78).

Key risks

  • ROIC Below WACC or Peers ROIC at 33.2th percentile suggests inefficient capital deployment.
  • Commodity Pressure / Weak Differentiation Gross margin at 38.8th percentile with high volatility suggests weak pricing power or commoditized products.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
57
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 60% Coverage
Trade-Off Triangle Visualization A ternary plot showing ATRA's balance between Growth (15.9%), Profitability (46.8%), and Safety (37.2%). Growth 16% Safety 37% Profitability 47%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

11th percentile vs peers
11
Key Signals
TSR -79.1% 11p
Strengths

No notable strengths identified for this axis.

Risks
  • Growth in bottom 20% of peers (percentile: 11)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

26th percentile vs peers
27
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Atara Biotherapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$28.64
- - -
+230.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000